These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19106256)

  • 1. Predicting the impact of the screening programme for colorectal cancer in the UK.
    Parkin DM; Tappenden P; Olsen AH; Patnick J; Sasieni P
    J Med Screen; 2008; 15(4):163-74. PubMed ID: 19106256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
    Hristova L; Hakama M
    Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of CT colonography for colorectal cancer screening on the UK NHS: costs, healthcare resources and health outcomes.
    Sweet A; Lee D; Gairy K; Phiri D; Reason T; Lock K
    Appl Health Econ Health Policy; 2011; 9(1):51-64. PubMed ID: 21174482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
    Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
    Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of CT colonography for UK NHS colorectal cancer screening of asymptomatic adults aged 60-69 years.
    Lee D; Muston D; Sweet A; Cunningham C; Slater A; Lock K
    Appl Health Econ Health Policy; 2010; 8(3):141-54. PubMed ID: 20369905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the cost-effectiveness of colorectal cancer screening: policy guidance based on patient preferences and compliance.
    Subramanian S; Bobashev G; Morris RJ
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):1971-8. PubMed ID: 19567507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Option appraisal of population-based colorectal cancer screening programmes in England.
    Tappenden P; Chilcott J; Eggington S; Patnick J; Sakai H; Karnon J
    Gut; 2007 May; 56(5):677-84. PubMed ID: 17142648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the UK colorectal cancer screening pilot studies on incidence, stage distribution and mortality trends.
    McClements PL; Madurasinghe V; Thomson CS; Fraser CG; Carey FA; Steele RJ; Lawrence G; Brewster DH
    Cancer Epidemiol; 2012 Aug; 36(4):e232-42. PubMed ID: 22425027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical management of small (6- to 9-mm) polyps detected at screening CT colonography: a cost-effectiveness analysis.
    Pickhardt PJ; Hassan C; Laghi A; Zullo A; Kim DH; Iafrate F; Morini S
    AJR Am J Roentgenol; 2008 Nov; 191(5):1509-16. PubMed ID: 18941093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Health economics analysis of colorectal screening].
    Boncz I; Sebestyén A; Dózsa C; Pál M; Sándor J; Palásti J; Betlehem J; Ember I
    Magy Onkol; 2004; 48(2):111-5. PubMed ID: 15351803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The case for population-based screening for colorectal cancer.
    Schoen RE
    Nat Rev Cancer; 2002 Jan; 2(1):65-70. PubMed ID: 11902587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
    Tsoi KK; Ng SS; Leung MC; Sung JJ
    Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colorectal cancer screening with faecal occult blood test within a multiple disease screening programme: an experience from Keelung, Taiwan.
    Yang KC; Liao CS; Chiu YH; Yen AM; Chen TH
    J Med Screen; 2006; 13 Suppl 1():S8-13. PubMed ID: 17227635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of colorectal cancer screening in Finland: experiences from the first three years of a public health programme.
    Malila N; Oivanen T; Hakama M
    Z Gastroenterol; 2008 Apr; 46 Suppl 1():S25-8. PubMed ID: 18368636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening and primary prevention of colorectal cancer: a review of sex-specific and site-specific differences.
    Massat NJ; Moss SM; Halloran SP; Duffy SW
    J Med Screen; 2013; 20(3):125-48. PubMed ID: 24197771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.
    Hardcastle JD; Chamberlain JO; Robinson MH; Moss SM; Amar SS; Balfour TW; James PD; Mangham CM
    Lancet; 1996 Nov; 348(9040):1472-7. PubMed ID: 8942775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of screening for colorectal cancer: a simulation model.
    Neilson AR; Whynes DK
    IMA J Math Appl Med Biol; 1995; 12(3-4):355-67. PubMed ID: 8919570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-stratified intensive follow up for treated colorectal cancer - realistic and cost saving?
    Macafee DA; Whynes DK; Scholefield JH
    Colorectal Dis; 2008 Mar; 10(3):222-30. PubMed ID: 17645572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model.
    Arrospide A; Idigoras I; Mar J; de Koning H; van der Meulen M; Soto-Gordoa M; Martinez-Llorente JM; Portillo I; Arana-Arri E; Ibarrondo O; Lansdorp-Vogelaar I
    BMC Cancer; 2018 Apr; 18(1):464. PubMed ID: 29695234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.